Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 9, 2010 - Issue 4
Submit an article Journal homepage
516
Views
14
CrossRef citations to date
0
Altmetric
Original Research

nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study

Mikhail Y Biakhov Semashko Clinical Hospital, #2, Moscow, Russia
, MD,
Galina V Kononova Arkhangelsk Regional Oncology Center, Arkhangelsk, Russia
, MD,
Jose Iglesias Abraxis BioScience, Los Angeles, CA, USA
, MD,
Neil Desai Abraxis BioScience, Los Angeles, CA, USA
, PhD,
Paul Bhar Abraxis BioScience, Los Angeles, CA, USA
, MS,
Anita N Schmid Abraxis BioScience, Los Angeles, CA, USA
, PhD &
Sibylle Loibl German Breast Group Forschungs GmbH, Schleussnerstrasse 42, 63263 Neu-Isenburg, Germany +49 0 6102 7480 426/418; +49 0 6102 7480 126; [email protected]
, MD show all
Pages 515-523 | Published online: 25 May 2010

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Markus Joerger. (2015) Metabolism of the taxanes including nab-paclitaxel. Expert Opinion on Drug Metabolism & Toxicology 11:5, pages 691-702.
Read now
Neha Gupta, Hassan Hatoum & Grace K Dy. (2014) First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel. International Journal of Nanomedicine 9, pages 209-221.
Read now

Articles from other publishers (12)

Marsilla Muth, Francis Williams Ojara, Charlotte Kloft & Markus Joerger. (2020) Role of TDM‐based dose adjustments for taxane anticancer drugs. British Journal of Clinical Pharmacology 87:2, pages 306-316.
Crossref
Lucía Ceniceros, Susana Prados & Rafael Alvarez Gallego. 2021. Textbook of Pancreatic Cancer. Textbook of Pancreatic Cancer 1215 1225 .
Hyunah Cho, Udayabhanu Jammalamadaka, Karthik Tappa, Christopher Egbulefu, Julie Prior, Rui Tang & Samuel Achilefu. (2019) 3D Printing of Poloxamer 407 Nanogel Discs and Their Applications in Adjuvant Ovarian Cancer Therapy. Molecular Pharmaceutics 16:2, pages 552-560.
Crossref
R. Álvarez, A. Carrato, J. Adeva, I. Alés, S. Prados, M. Valladares, T. Macarulla, A. Muñoz & M. Hidalgo. (2018) Management of hyperbilirubinaemia in pancreatic cancer patients. European Journal of Cancer 94, pages 26-36.
Crossref
Sailaja Kamaraju, Jill Depke, Janice Povletich, Adam Currey & Elizabeth Weil. (2016) Cutaneous Metastasis due to Breast Cancer in a Patient with Primary Biliary Cirrhosis: A Case Report. Case Reports in Oncology 9:3, pages 718-725.
Crossref
Markus Joerger. (2015) Treatment regimens of classical and newer taxanes. Cancer Chemotherapy and Pharmacology 77:2, pages 221-233.
Crossref
Arndt Vogel, Frank Kullmann, Volker Kunzmann, Salah-Eddin Al-Batran, Helmut Oettle, Ruben Plentz, Jens Siveke, Christoph Springfeld & Hanno Riess. (2015) Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine. Oncology Research and Treatment 38:11, pages 596-603.
Crossref
Nianhang Chen, Yan Li, Ying Ye, Maria Palmisano, Rajesh Chopra & Simon Zhou. (2014) Pharmacokinetics and pharmacodynamics of nab ‐paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent‐based paclitaxel . The Journal of Clinical Pharmacology 54:10, pages 1097-1107.
Crossref
Courtney E. PorterJ. Aubrey Waddell & Dominic A. SolimandoJrJr. (2014) nab -Paclitaxel Plus Gemcitabine Regimen for Pancreatic Cancer . Hospital Pharmacy 49:1, pages 18-22.
Crossref
Sihem Ait-Oudhia, Robert M. Straubinger & Donald E. Mager. (2012) Meta-analysis of Nanoparticulate Paclitaxel Delivery System Pharmacokinetics and Model Prediction of Associated Neutropenia. Pharmaceutical Research 29:10, pages 2833-2844.
Crossref
Ruth Duncan & Rogerio Gaspar. (2011) Nanomedicine(s) under the Microscope. Molecular Pharmaceutics 8:6, pages 2101-2141.
Crossref
Margaret Barh, Debmalya Blum & Kenneth MadiganSandhiya Selvarajan. 2011. OMICS. OMICS 101 118 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.